Dermatology News

If early therapy with DMARDs can slow disease progression and delay expensive biologic treatment, early screening for psoriatic arthritis among patients with psoriasis could save $220 million each year in Canada and improve quality of life, according to data published in Arthritis Care & Research.

Patients with psoriasis or psoriatic arthritis who are newly treated with IL-12/23 blockers demonstrated a reduced risk for serious infection compared with those who received TNF or IL-17 inhibitors, according to data published in Annals of the Rheumatic Diseases.

ATLANTA — Patients with juvenile dermatomyositis demonstrate obvious mitochondrial abnormalities in the tissue and periphery, supporting the use of anti-mitochondrial antibodies as a prognostic marker, according to data presented at ACR/ARP 2019.

ATLANTA — The use of either non-TNF inhibitor biologics or tofacitinib for chronic inflammatory diseases during pregnancy did not significantly increase risk for serious infections among infants, according to findings presented at the 2019 ACR/ARP Annual Meeting.

WASHINGTON — Difelikefalin significantly reduced itch intensity and was linked to an increase in quality of life for patients on hemodialysis who had moderate to severe pruritus, according to phase 3 data presented at ASN Kidney Week.

Children with either inflammatory bowel disease, chronic noninfectious osteomyelitis or juvenile idiopathic arthritis developed psoriasis at an increased rate compared with the general public, with the highest rates seen among those treated with TNF inhibitors, according to data published in Arthritis Care & Research.

The common historical approach of “wait and see” for infantile hemangiomas can lead to bad outcomes, according to Lawrence A. Schachner, MD, a dermatologist and pediatrician.

Among systemic rheumatic diseases, the risk for opportunistic infection is highest among patients with polymyositis or dermatomyositis, followed by systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis and primary Sjögren’s syndrome, according to data published in Arthritis Research & Therapy.

Johnson & Johnson is voluntarily recalling one lot of its Johnson’s Baby Powder product due to the presence of asbestos, according to a press release from the FDA.

The FDA recently approved Galderma’s topical retinoid cream, known as Aklief, for the treatment of acne vulgaris.